South & Central America Botulinum Toxin Market Forecast to 2031 - Regional Analysis - by Product, Application, and End User

The South & Central America botulinum toxin market was valued at US$ 280.48 million in 2023 and is expected to reach US$ 766.64 million by 2031; it is estimated to register a CAGR of 13.4% from 2023 to 2031.

Expanding Therapeutic Applications Fuel South & Central America Botulinum Toxin Market

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures.

Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure.

For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.

South & Central America Botulinum Toxin Market Overview

The botulinum toxin market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Market growth in this region is mainly driven by the rising public awareness about cosmetic procedures, the accessibility of technologically advanced user-friendly products, and the increasing demand for aesthetic treatments.

In Brazil, minimally invasive and noninvasive cosmetic procedures are being performed for the treatment of a broad range of indications. BOTOX, Xeomin, Dysport, Botulift, and Prosigne are among the botulinum toxin A formulations available in Brazil. The ISAPS report reveals that botulinum toxin-based treatment was the most common non-surgical procedure performed in Brazil in 2021.

Nearly 542,520 botulinum toxin procedures, accounting for 49.8% of the total nonsurgical procedures, were performed in the country in the said year. Moreover, the presence of key players positively impacts the growth of the botulinum toxin market in Brazil. In February 2020, Daewoong Pharmaceuticals announced receiving approval from ANVISA for using and selling Nabota, a botulinum toxin product type, in Brazil. Also, Hugel, one of the prominent aesthetics and therapeutics companies, has marketed its botulinum toxin brand in 27 countries, including Brazil.

South & Central America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

South & Central America Botulinum Toxin Market Segmentation

The South & Central America botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the South & Central America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of South & Central America botulinum toxin market share in 2023.

In terms of application, the South & Central America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of South & Central America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the South & Central America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of South & Central America botulinum toxin market in 2023.

Based on country, the South & Central America botulinum toxin market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Medytox Inc, and Galderma SA are some of the leading companies operating in the South & Central America botulinum toxin market.